Skip to main content

Lung Cancer

A Look at PD-1 and PD-L1 Inhibitors

Edward Garon, MD

Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation

Wayne Kuznar

Afatinib Boosts PFS in EGFR Mutation–Positive Lung Cancer

Afatinib Doubles Progression-Free Survival Compared with Chemotherapy in Patients with Lung Cancer

Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer

Alectinib Potential First-Line Treatment for NSCLC Associated with ALK Mutation

ALK Gene Rearrangement and PD-L1 Expression

Edward Garon, MD

Lung Cancer, Select Drug Profiles, Payers' Guide

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh

Conference Highlights ASCO, Lung Cancer

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion

Wayne Kuznar

Play Video

1
2
3
4

Page 1 of 5
Results 1 - 10 of 44

SUBSCRIBE

HOME

ABOUT

CONTACT US

TERMS OF USE

PRIVACY POLICY

ADVERTISING POLICY

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Special Print Editions

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.